Drugs / L-serine
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Maapliv | — | 2025-07-28 | europa.eu ↗ |
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT06967428 | Sep 2025 → Jan 2026 overdue | — | Independent Medical Alliance | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT03580616 | Oct 2018 → Aug 2022 | amyotrophic lateral sclerosis | Elijah W. Stommel | Terminated | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07342439 | Sep 2026 → Nov 2029 expected | macular telangiectasia type 2 | The Lowy Medical Research Institute Limited | Not yet recruiting | No outcome recorded |
Also used as a comparator or background therapy in 4 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT01733407 Comparator | Sep 2013 → May 2016 | hereditary sensory and autonomic neuropathy type 1 | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 1/2 | NCT01835782 Comparator | Jan 2013 → Dec 2016 | amyotrophic lateral sclerosis | Phoenix Neurological Associates, LTD | Unknown | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06113055 Comparator | Aug 2023 → Aug 2025 | hereditary sensory and autonomic neuropathy type 1 | University College, London | Unknown | No outcome recorded |
| Phase 2 | NCT03062449 Comparator | Mar 2017 → Jul 2021 | Alzheimer disease | Aleksandra Stark | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | L-serine | “This daily intervention over 3 months combines 4 g L-serine, 14 g L-glutamine, 3 g L-arginine, 2.5 g N-acetylcysteine, 5.75 g L-citrulline, 1 g vitamin C, and 5 g creatine to...” NCT06967428 ↗ |
| Known as | (S)-2-amino-3-hydroxypropanoic acid | “L-serine (C3H7NO3; 105.09 g/mol; synonym (S)-2-amino-3-hydroxypropanoic acid) is a naturally-occurring dietary amino acid.” NCT03062449 ↗ |
| Modality | Other / unclassified | “amino acid supplementation with L-serine” NCT01733407 ↗ |
| Route | Oral | “High-dose oral l-serine supplementation appears safe in patients with HSAN1” PMID 30626650 ↗ Jan 2019 |